Biocad sets sights on being leading supplier of cancer drugs in Russia

11 August 2022

Russian drugmaker Biocad is eyeing becoming the largest supplier of oncology drugs for state needs, achieving this by producing analogues of some popular drugs for the treatment of cancer. For example, the company was the first in Russia to start clinical trials of pertuzumab, an analogue of Swiss pharma giant Roche's (ROG: SIX) Perjeta drug, and is registering a pembrolizumab-based generic at present, reports The Pharma Letter’s local correspondent.

According to the Russian Kommersant business paper, so far Biocad has received permission from the Ministry of Health for comparative clinical trials of the first phase of the drug used in the treatment of breast cancer based on pertuzumab and Roche’s Perjeta.

Pertuzumab is used together with trastuzumab, an analogue – also termed a biosimilar for biologicals - which is already produced by Biocad. The patent for pertuzumab expires in Europe in March 2023 and in the USA in June 2024, and Biocad became the first company in the Russian Federation to start testing the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK